These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23695184)

  • 1. Logistic regression in signal detection: another piece added to the puzzle.
    Caster O; Norén GN; Madigan D; Bate A
    Clin Pharmacol Ther; 2013 Sep; 94(3):312. PubMed ID: 23695184
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to "Logistic regression in signal detection: another piece added to the puzzle".
    Harpaz R; DuMouchel W; LePendu P; Bauer-Mehren A; Ryan P; Shah NH
    Clin Pharmacol Ther; 2013 Sep; 94(3):313. PubMed ID: 23756371
    [No Abstract]   [Full Text] [Related]  

  • 3. Advancing the science of pharmacovigilance.
    Honig PK
    Clin Pharmacol Ther; 2013 Jun; 93(6):474-5. PubMed ID: 23689213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system.
    Harpaz R; DuMouchel W; LePendu P; Bauer-Mehren A; Ryan P; Shah NH
    Clin Pharmacol Ther; 2013 Jun; 93(6):539-46. PubMed ID: 23571771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stevens-Johnson syndrome and toxic epidermal necrolysis: the Food and Drug Administration adverse event reporting system, 2004-2013.
    Abe J; Mataki K; Umetsu R; Ueda N; Kato Y; Nakayama Y; Kinosada Y; Hara H; Inagaki N; Nakamura M
    Allergol Int; 2015 Jul; 64(3):277-9. PubMed ID: 26117261
    [No Abstract]   [Full Text] [Related]  

  • 6. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.
    Stobaugh DJ; Deepak P; Ehrenpreis ED
    J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the MedDRA hierarchy on pharmacovigilance data mining results.
    Pearson RK; Hauben M; Goldsmith DI; Gould AL; Madigan D; O'Hara DJ; Reisinger SJ; Hochberg AM
    Int J Med Inform; 2009 Dec; 78(12):e97-e103. PubMed ID: 19230751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data.
    Ibrahim H; Saad A; Abdo A; Sharaf Eldin A
    J Biomed Inform; 2016 Apr; 60():294-308. PubMed ID: 26903152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions.
    Hauben M; Horn S; Reich L
    Drug Saf; 2007; 30(2):143-55. PubMed ID: 17253879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of statistical signal detection methods within and across spontaneous reporting databases.
    Candore G; Juhlin K; Manlik K; Thakrar B; Quarcoo N; Seabroke S; Wisniewski A; Slattery J
    Drug Saf; 2015 Jun; 38(6):577-87. PubMed ID: 25899605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of statistical shrinkage parameters of disproportionality methods in spontaneous reporting system of China.
    Wang J; Ye XF; Guo XJ; Zhu TT; Qi N; Hou YF; Zhang TY; Shi WT; Wei X; Liu YZ; Wu GZ; He J
    Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):962-70. PubMed ID: 26095121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian hierarchical modeling for detecting safety signals in clinical trials.
    Xia HA; Ma H; Carlin BP
    J Biopharm Stat; 2011 Sep; 21(5):1006-29. PubMed ID: 21830928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of Spontaneously Reported Adverse Events].
    Nakamura M
    Yakugaku Zasshi; 2016; 136(4):549-56. PubMed ID: 27040337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
    Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
    Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of measures of disproportionality in pharmacovigilance: three Dutch examples.
    Egberts AC; Meyboom RH; van Puijenbroek EP
    Drug Saf; 2002; 25(6):453-8. PubMed ID: 12071783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A challenge to the data miners.
    Lilienfeld DE;
    Pharmacoepidemiol Drug Saf; 2004 Dec; 13(12):881-4. PubMed ID: 15558812
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of data mining in pharmacovigilance.
    Hauben M; Madigan D; Gerrits CM; Walsh L; Van Puijenbroek EP
    Expert Opin Drug Saf; 2005 Sep; 4(5):929-48. PubMed ID: 16111454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Big Data and Adverse Drug Reaction Detection.
    Harpaz R; DuMochel W; Shah NH
    Clin Pharmacol Ther; 2016 Mar; 99(3):268-70. PubMed ID: 26575203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms.
    Hauben M; Reich L; Chung S
    Eur J Clin Pharmacol; 2004 Dec; 60(10):747-50. PubMed ID: 15619136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.